Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Daily News

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Todd Neale

December 20, 2024

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Conference News AHA 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

Shelley Wood

November 15, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

News Daily News

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Yael L. Maxwell

November 05, 2018

News Features

Cardiologists Treating Syrian Refugees Call Missions an ‘Addictive’ Passion That Saves Lives

Yael L. Maxwell

January 12, 2018

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Industry News

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

August 15, 2017

News Daily News

在出血风险高的患者中新一代 DES 加简化 DAPT 优于 BMS

L.A. McKeown

March 08, 2016

News Daily News

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

L.A. McKeown

March 08, 2016

News Daily News

Los SLF de Nueva Generación Con Tratamiento Antiplaquetario Doble Abreviado Superan a los SMD en Pacientes de Alto Riesgo Hemorrágico

L.A. McKeown

March 08, 2016

Presentation TCT 2014

Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE

Presenter: Fausto Feres

September 16, 2014

Presentation TCT 2014

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

Presenter: Dietmar Trenk, Harvey D. White, Dominick J. Angiolillo, Fausto Feres

September 14, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Daily News

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Jason Kahn

January 22, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

News Daily News

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

September 20, 2012

News Daily News

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

September 20, 2012

News Daily News

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

April 03, 2012

Advertisement

BMJ Investigation Revives Questions About PLATO, Ticagrelor

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Cardiologists Treating Syrian Refugees Call Missions an ‘Addictive’ Passion That Saves Lives

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

在出血风险高的患者中新一代 DES 加简化 DAPT 优于 BMS

Newer-Generation DES With Abbreviated DAPT Bests BMS in Patients at High Risk for Bleeding

Los SLF de Nueva Generación Con Tratamiento Antiplaquetario Doble Abreviado Superan a los SMD en Pacientes de Alto Riesgo Hemorrágico

Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE

TCT 481: Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus-Eluting Stent Implantation in OPTIMIZE

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content